A Global Community

8,000+ professionals in over 90 countries


Experienced Practitioners:

Real-world experience and insight in IP and licensing transactions.

Get Involved

A Wealth of Deal Making Resources

Royalty Rate surveys, templates and more resources to help you succeed

Learn More

The LES community drives strategy, transactions, and deals involving intellectual property, business and law to fuel the evolving innovation economy.

Become More with LES!

When you join LES, you become part of a community of the best and brightest minds in the IP ecosystem. Expand your network and your knowledge, join LES today!

Join LES Today

Enhance Your Skills to Enhance Your Career

Learn from the experts through LES courses and workshops.

Learn More

Young Members Congress (YMC): The Future of LES

Calling all IP/Licensing/tech transfer professionals under the age of 40! YMC offers networking, professional growth and development support to maximize your career opportunities. Get involved and help shape the LES of the future.

Women in LES

LES women members connect for networking and sharing best practices.

Public Policy and Standards Initiatives

In these ever-evolving arenas of Public Policy and Standards Initiatives, LES is on the front lines in helping to shape the future of IP commerce.

Thank you to our sponsors!

Want to see your logo here? Learn More


  • Program:
    The Licensing Executive Society Silicon Valley Chapter is pleased to present this webinar in which leading experts will provide
    . . . insight on trade secrets as companies face mounting challenges of workforce mobility/technology usage and related trade secret misappropriation, evolving IP laws, and new options to fund litigation.
    This program will showcase the findings of Stout’s newly released “Trends in Trade Secrets Litigation Report 2020,” which covers trade secret litigation trends across the types of trade secrets, industries, jurisdictions, damages, and companies. Registrants will be provided with a copy of the report prior to the webinar for review and to have questions ready.
    Our expert panel will further explore the various aspects of securing trade secrets and financing the litigation process, including:
    Impact of the Defend Trade Secrets Act of 2016 (DTSA) and its influence on how businesses protect their intellectual property.
    Securing an injunction for trade secret misappropriation.
    The corporate view and best practices for trade secret protection
    Trade secret litigation from the point of view of funders and companies/attorneys seeking funding.
    Examining various options that are available
    Trade secret cases most suitable for litigation
    Typical litigation funding deal structures
    Process details and how long it could take
    Other important considerations/lessons learned
    Moderator: Michael Pierantozzi, Principal/Owner, Andiamo Associates, LLC
    Neil Eisgruber, Director, Disputes, Compliance, & Investigations, Stout
    Author, Trade Secrets Report, Trends in Trade Secret Litigation Report 2020, Stout
    Jeremy Elman, Counsel, White & Case LLP
    Michael Kallus, Senior Investment Manager, Woodsford Litigation Funding
    Deanna Kwong, Senior IP Litigation Counsel, Hewlett Packard Enterprise
    Mitch Rosenfeld, Managing Director, Intellectual Property Advisory & Transactions, Stout

  • Program:
    Pharmaceutical Industry: The Case of Brand vs Generic Products
    The drug patent system was created to reward pharma companies for
    . . . innovation and ensure returns on investment. IP protection and commercial exclusivity regulated by the Drug Price Competition and Patent Restoration Act (Hatch-Waxman Act) provides protection to drug innovators and also provides the pathway for generic manufacturers to challenge NDA holders patent(s) and apply for a PIV-Abbreviated New Drug Application ( ANDA) for approval of a generic product prior to the expiration of the innovator product patents. Resolution of patent infringement becomes the subject of a litigation.
    Intellectual Property litigation in the pharmaceutical industry will be the subject of discussion of our next webinar series. Our panel of experienced experts have represented either the brand or generic side of this dynamic and will present a three- part overview of these and related issues.
    Part 2: Patent Infringement Lawsuit
    • ANDAs, 502(b) applications, Biosimilars and PIV notices; Confidential Access; Hatch-Waxman case timing, venue, court rules and mandatory disclosures; Inducement of Infringement; Unlisted patents; and Manufacturing patents.
    Daisy Daisy Rivera-Muzzio, R.Ph, MS, MBA, President of Acumen Biopharma
    Josh Reisberg, Esq., Partner at Axinn
    Shane A. Brunner, J.D., Partner at Michael Best
    Jeffrey I. D. Lewis, J.D., Partner at Foley Hoag’s New York


  • Diverse Group of Intellectual Property and Licensing Leaders Representing Organizations of All. . .

  • Granting or recording a security interest in a patent at the USPTO does not deprive the patent. . .

  • To avoid an allegation that a patent assignor is estopped from arguing that an asserted patent is. . .